Table 13 Liquid biopsy in reproductive system cancers
From: Liquid biopsy in cancer: current status, challenges and future prospects
Cancer | Liquid biomarker | Origin | Tendency | Downstream target | Function | Reference |
|---|---|---|---|---|---|---|
Cervical cancer | CTCs | Peripheral blood | up | Â | Prognostic biomarker | |
ccfHPV-DNA | Plasma | Â | Â | Efficacy monitoring biomarker | ||
HOTAIR, PVT1, XLOC_000303, AL592284.1 | Plasma | up | Â | Early diagnostic biomarker | ||
miR-21, -25, -29a, -200a, -486-5p | Serum | up | Â | Early diagnostic biomarker, Disease progression biomarker | ||
miR-196a | Serum | up | Â | Disease progression biomarker, Prognostic biomarker | ||
miR-425-5p | Serum | up | Â | Prognostic biomarker | ||
ESR1, ERBB2 mutation | Plasma | up | Â | Efficacy monitoring biomarker | ||
Endometrial cancer | CTCs | Peripheral blood | up | Â | Early diagnostic biomarker | |
CK-20 | Peripheral blood | up | Â | Tumor aggressiveness biomarker, Tumor recurrence biomarker | ||
CTNNB1, KRAS, PTEN, PIK3CA | Plasma | up | Â | Tumor recurrence biomarker, Efficacy monitoring biomarker | ||
DNA methylation | Urine | up | Â | Early diagnostic biomarker | ||
Ovarian Cancer | claudin | Serum exosome | up | Â | Early diagnostic biomarker | |
miR-1307, miR-375 | Serum exosome | up | Â | Early diagnostic biomarker | ||
Prostatic carcinoma | CTCs | Peripheral blood | up | Â | Prognostic biomarker | |
cfDNA mutation | Serum | up | Â | Early diagnostic biomarker | ||
cfDNA | Plasma | up | Â | Efficacy monitoring biomarker, Prognostic biomarker | ||
miR-21 | Serum | up | Â | Efficacy monitoring biomarker | ||
miR-141, miR-146b-3p, miR-194 | Serum | up | Â | Prognostic biomarker |
